« Return to News | CROs/Service Providers

Averion Expands European Operations

Wednesday, October 8, 2008 01:06 PM

Averion, a contract research organization (CRO) specializing in oncology, cardiovascular diseases and medical devices, has expanded its European operations by opening an office in the Czech Republic.

"Averion continues to expand its European footprint to meet the needs of our clients with the opening of the Averion Czech Republic office," said Averion CEO Dr. Markus Weissbach, in a company release. "In the heart of Central Eastern Europe, the Czech Republic offers a strong clinical trial environment with large patient populations and well-qualified investigators in a broad range of indications.”

Averion is headquartered in Southborough, Mass., with European operations in Basel, Switzerland. The CRO has additional U.S. offices in California, Maryland and New York; and additional offices outside the U.S. in France, the Netherlands, the United Kingdom, Poland, Russia, Israel, Germany, Austria, Ukraine and, now, the Czech Republic.

Dr. Libor Hubacek, country manager for Averion in the Czech Republic, will oversee monitoring and regulatory activities for studies conducted in Averion’s new Prague office. Hubacek has more than 10 years of experience in monitoring, submissions and management of clinical trials in the Czech Republic. Averion expects to hire additional staff for the Czech office in the coming months.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.